William D. Chey
University of Michigan
DefecationInternal medicineSurgeryRandomized controlled trialIntensive care medicinePhysical therapyPlaceboHelicobacter pyloriBloatingIrritable bowel syndromeDiseaseMEDLINEDiarrheaAbdominal painConstipationPopulationChronic constipationIn patientMedicineGastroenterology
Publications 600
#1Nicholas J. Talley (University of Newcastle)H-Index: 183
#2Amol P. KambojH-Index: 2
Last. Anthony Lembo (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 71
view all 18 authors...
#1Eric D. Shah (Dartmouth College)H-Index: 8
#2Kyle Staller (Harvard University)H-Index: 13
Last. William D. CheyH-Index: 78
view all 9 authors...
INTRODUCTION Chronic idiopathic constipation (CIC) is a common and burdensome illness. We performed a cost-effectiveness analysis of the US Food and Drug Administration-approved CIC drugs to evaluate and quantify treatment preferences compared with usual care from insurer and patient perspectives. METHODS We evaluated the subset of patients with CIC and documented failure of over-the-counter (OTC) osmotic or bulk-forming laxatives. A RAND/UCLA consensus panel of 8 neurogastroenterologists inform...
#1Maria Andrea Azcarate-Peril (UNC: University of North Carolina at Chapel Hill)H-Index: 8
#2Jeff Roach (UNC: University of North Carolina at Chapel Hill)H-Index: 3
Last. Todd R. Klaenhammer (NCSU: North Carolina State University)H-Index: 102
view all 8 authors...
Background. Our recent publication (Chey et al., Nutrients 2020) showed that a 30-day administration of pure galacto-oligosaccharides (GOS) significantly reduced symptoms and altered the fecal micr...
#1Adrienne Lenhart (UCLA: University of California, Los Angeles)H-Index: 3
#2William D. Chey (UM: University of Michigan)H-Index: 78
Last. Shanti Eswaran (UM: University of Michigan)H-Index: 14
view all 3 authors...
Our review focuses on the various presentations, diagnosis, and treatment of sucrose–isomaltase deficiency (SID), previously thought to be limited to the pediatric population with severe malabsorptive symptoms. Although sucrase–isomaltase deficiency is presumed to be a rare disorder, it is likely under recognized and more prevalent than is currently known. Congenital sucrase–isomaltase deficiency usually manifests early in life, but the phenotype may vary depending on the mutation(s) present. SI...
Irritable bowel syndrome (IBS) is a common symptom-based condition of heterogeneous pathogenesis and clinical phenotype. This heterogeneity and multidimensional nature creates significant diagnostic and treatment challenges. Recent evidence has documented the benefits of diet and behavioral interventions. These nonmedical strategies are causing a shift from the traditional care model to a multidisciplinary care model. Recent evidence suggests that collaborative, team-based integrated care leads ...
INTRODUCTION Psyllium and prunes are proven treatments for chronic constipation (CC). Asian studies suggest that kiwifruit may also benefit CC symptoms. We report a partially randomized, comparative effectiveness trial evaluating kiwifruit, psyllium, and prunes in US patients with CC. METHODS Adults with CC at a US medical center were randomized to 3 natural treatments. Eligible patients had ≤3 complete spontaneous bowel movements (CSBMs) per week and were partially randomized to green kiwifruit...
3 CitationsSource
#1William D. Chey (UM: University of Michigan)H-Index: 78
#2Anthony Lembo (BIDMC: Beth Israel Deaconess Medical Center)H-Index: 71
Last. David P. RosenbaumH-Index: 6
view all 4 authors...
INTRODUCTION Tenapanor is a first-in-class, minimally absorbed, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger isoform 3. This phase 3 trial assessed the long-term efficacy and safety of tenapanor 50 mg b.i.d. for the treatment of patients with irritable bowel syndrome with constipation (IBS-C). METHODS In this randomized double-blind study (ClinicalTrials.gov identifier: NCT02686138), patients with IBS-C received tenapanor 50 mg b.i.d. or placebo b.i.d. for 26 weeks....
4 CitationsSource
#1Eric D. Shah (Dartmouth–Hitchcock Medical Center)H-Index: 8
#2Brian E. Lacy (Mayo Clinic)H-Index: 54
Last. Darren M. Brenner (NU: Northwestern University)H-Index: 17
view all 5 authors...
INTRODUCTION Tegaserod was the first US Food and Drug Administration-approved drug for irritable bowel syndrome with constipation (IBS-C) in women and was recently reapproved for use. Recognizing that clinical trials were performed almost 20 years ago, we performed an integrated analysis on patient-reported outcomes relevant to current practice including previously unpublished data. METHODS Data from 4 12-week, randomized, placebo-controlled trials evaluating tegaserod 6 mg b.i.d. in patients wi...
1 CitationsSource